Guideline on good pharmacovigilance practices …

9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25

  Good, Practices

Guideline on good pharmacovigilance practices …

Guideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

Guideline for good clinical practice E6(R2)

Guideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification

  Good, Practices, Clinical, Good clinical practice

Guideline for good clinical practice E6(R2)

Guideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November

  Guidelines, Good, Practices, Clinical, Good clinical practice e6

Guideline on good pharmacovigilance practices …

harmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

European Medicines Agency

© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline

  Guidelines, European, Agency, Medicine, Harmonised, European medicines agency, Ich harmonised

products1/traditional herbal medicinal products

There is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already

  Product, Medicinal, Traditional, Herbal, Products1 traditional herbal medicinal products, Products1

Q7 Q&A - good manufacturing practice for active ...

ICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37

  Good, Practices, Pharmaceutical, Manufacturing, Active, Ingredients, Good manufacturing practice for active, Good manufacturing practice for active pharmaceutical ingredients

Electronic submission of Article 57(2) data …

Electronic submission of Article 57(2) data EMA/159776/2013 Page 3/75 3.5. Submission of medicinal products with different authorisation number for each package

  Product, Electronic, Article, Medicinal, Submissions, Electronic submission of article 57, Medicinal products

CMC Regulatory Considerations for …

CMC Regulatory Considerations for Oligonucleotide Drug Products: FDA Perspective Mohan Sapru, M.S., Ph.D. CMC Lead for Cardiovascular and Renal Products

  Drug, Regulatory, Considerations, Cmc regulatory considerations for, Cmc regulatory considerations for oligonucleotide drug, Oligonucleotide

Final Concept Paper Q12: Technical and Regulatory ...

FINAL Q12 Concept Paper Endorsed: 9 September 2014 -2- An ICH harmonised approach on technical and regulatory considerations for lifecycle

  Regulatory, Concept paper, Concept, Paper, Considerations, Regulatory considerations

Industry Book of Knowledge - CMC Drug Product …

Industry Book of Knowledge Practical Considerations for eCTD Submissions: Quality Overall Summary (QOS) for Marketing Applications A compilation of points to consider based on collective experiences from: Abbott, Amgen,

  Industry, Book, Knowledge, Considerations, Industry book of knowledge

gfi cmc nasal spray - gmpeye.co.kr

Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products – Chemistry, Manufacturing, and Controls Documentation